Anti-Siglec-2/CD22 Antibody (Pinatuzumab vedotin)
Catalog No.
F1129
Anti-Siglec-2/CD22 Antibody (Pinatuzumab vedotin)
Featured Products
Pinatuzumab Vedotin (RG-7593, DCDT2980S, DCDT-2989S) is an antibody-drug conjugate (ADC) CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte adhesion molecule, BL-CAM, Leu-14) Antibodies and cytotoxic agentsMonomethyl auristatin E (MMAE) conjugated via a maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.
Quality Control & DataSheet
- View current batch:
-
Purity > 90% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
151.97 kDa
Dry ice
1313706-14-7
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
RG7593, DCDT2980S, 10F4
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P20273
Human
MMAE
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
The drug-to-antibody ratio (DAR) of the Anti-Siglec-2 / CD22 Reference Antibody (Pinatuzumab vedotin) is 4.3.
Siglec-2 / CD22
Please avoid freeze-thaw cycles.